89483-08-9

Basic information

• Product Name: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid
• Synonyms: (R)-2-(Boc-amino)-3-cyclopropylpropionic acid;N-Boc-R-3-Cyclopropylalanine
• CAS NO: 89483-08-9
• Molecular Formula: C11H19NO4
• Molecular Weight: 229.27286
• Mol File: 89483-08-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid(89483-08-9)
• EPA Substance Registry System: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid(89483-08-9)

Safety Data

• Hazardous Substances Data: 89483-08-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid is used as a building block in the synthesis of various peptides and other biologically active compounds. Its unique molecular structure allows for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry:
(R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid is utilized for its potential therapeutic properties, including anti-inflammatory and analgesic effects. Its versatility in the design and synthesis of pharmaceuticals makes it an important chemical in the field of medicinal chemistry.
Used in Drug Development:
In the pharmaceutical industry, (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid is used as a key component in the development of new drugs. Its ability to be incorporated into various peptide structures and its protective tert-butoxycarbonyl group make it a valuable asset in creating effective and targeted medications.

Upstream product

• 33574-02-6 cyclopropylmethyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 170115-96-5 2-amino-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylacetamide 
• 170642-22-5 (R)-2-Amino-3-cyclopropyl-N-((1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-N-methyl-propionamide 
• 121786-39-8 (R)-2-amino-3-cyclopropylpropanoic acid 
• 102735-53-5 (2S)-2-amino-3-cyclopropylpropanoic acid 
• 104347-84-4 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoate 
• 34619-03-9 tert-butyldicarbonate 

Relevant articles and documents

TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS

This application relates to novel substituted azacyclohexyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPA).

Inhibitors of cysteine proteases and methods of use thereof

The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Exemplary compounds provided include Formula II-I, where R3, RB are provided herein:

Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation

The discovery of natural specialized pro-resolving mediators and their corresponding receptors, such as formyl peptide receptor 2 (FPR2), indicated that resolution of inflammation (RoI) is an active process which could be harnessed for innovative approaches to tame pathologies with underlying chronic inflammation. In this work, homology modelling, molecular docking and pharmacophore studies were deployed to assist the rationalization of the structure-activity relationships of known FPR2 agonists. The developed pharmacophore hypothesis was then used in parallel with the homology model for the design of novel ligand structures and in virtual screening. In the first round of optimization compound 8, with a cyclopentane core, was chosen as the most promising agonist (β-arrestin recruitment EC50 = 20 nM and calcium mobilization EC50 = 740 nM). In a human neutrophil static adhesion assay, compound 8 decreased the number of adherent neutrophils in a concentration dependent manner. Further investigation led to the more rigid cycloleucines (compound 22 and 24) with improved ADME profiles and maintaining FPR2 activity. Overall, we identified novel cyclopentane urea FPR2 agonists with promising ADMET profiles and the ability to suppress the inflammatory process by inhibiting the neutrophil adhesion cascade, which indicates their anti-inflammatory and pro-resolving properties.

Substituted Pyrrolidine Amides II

The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.

5-AMINO-4-CARBAMOYL-PYRAZOLE COMPOUNDS AS SELECTIVE AND IRREVERSIBLE T790M OVER WT-EGFR KINASE INHIBITORS AND USE THEREOF????

Disclosed are compounds of Formula (I), pharmaceutical compositions comprising the same, processes for the preparation thereof, and the use thereof.

BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.

Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily

The present invention relates to compounds and pharmaceutical compositions which inhibit proteases, such as cysteine proteases. In particular, the present invention relates to compounds and pharmaceutical compositions which inhibit cysteine proteases of the papain superfamily. The compounds and pharmaceutical compositions of the present invention are useful for treating diseases, particularly parasitic diseases, which are mediated by such proteases. In particular, the present invention relates to a method of treating malaria by inhibiting the cysteine protease falcipain.